Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy

In a study involving 31 patients with ovarian cancer undergoing chemotherapy, selenium (Se) supplementation at a daily dose of 200 μg resulted in significant increases in Se concentration in serum and hair, as well as increased activity of glutathione peroxidase (GSH-Px) in erythrocytes after 2 and 3 months. Additionally, there was a significant increase in malondialdehyde (MDA) levels and white blood cell (WBC) count after 3 months of supplementation. Notably, the study also found a significant decrease in hair loss, flatulence, abdominal pain, weakness, malaise, and loss of appetite after 2 and 3 months of Se administration. The study concluded that selenium has beneficial effects when used as a supportive element in chemotherapy for ovarian cancer patients.